Search
Lansoprazole
go.drugbank.com/drugs/DB00448ApprovedInvestigationalalong with other pathologies caused by excessive acid secretion. … [A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD)
Products: Nb-lansoprazoleUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.
Ambroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalSurfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. … It stimulates synthesis and release of surfactant by type II pneumocytes.
Mixtures: TUSIGEN NF, HISTIACIL NFSynonyms: N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol, N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanolBendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawna small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation. … Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSCalcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … It is also present in dental or oral hygiene products due to its cariostatic effects.
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnElixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies. … It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] … The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeInternational brands: CO OlanzapineCetirizine
go.drugbank.com/drugs/DB00341ApprovedInvestigationalThe prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. … Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects [A175060].
Mixtures: Allergy and Congestion Relief D Original Prescription Strength, VERACETAM NF CAPSULASCategories: Histamine H1 Antagonists, Non-SedatingDaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Products: CUBICIN® 350 MG POLVO PARA SOLUCIÓN INYECTABLE O INFUSIÓN, CUBICIN® 500 MG POLVO PARA SOLUCION INYECTABLE O INFUSIONNorfloxacin
go.drugbank.com/drugs/DB01059ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Products: N-FLOXA 200, N-FLOXA 400